Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter aims to speed recovery in ICU patients on life support

NCT ID NCT06179771

Disease control Sponsor: University Hospitals, Leicester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a blood filter called HA380 in 40 critically ill adults (ages 18-65) who need dialysis or ECMO due to severe infection, injury, or major surgery. The filter is added to their life-support circuit to remove inflammatory substances from the blood. Researchers want to see if this approach is practical and whether it reduces time on breathing machines, blood pressure drugs, and in the ICU.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Consent obtained * Male or Female, aged 18 years - 65 years. * Admitted with a diagnosis of sepsis (according to sepsis-3 definition), trauma, ARDS of infectious or non-infectious aetiology, trauma or after major surgery * Need for extracorporeal support and specifically renal replacement therapy (RRT) and/or ECMO. * Vasopressor or inotropic therapy requirement at the time of RRT or ECMO support * Within 72 hours of requiring extracorporeal support * At least one of: * CRP \> 100 mg/L (in the absence of immunosuppressive therapy/immunomodulation) * Lactate \>2 mmol/L Exclusion Criteria * The participant may not enter the trial if ANY of the following apply: * Unable to obtain consent. * Expected to die in the next 24 hours. * Pre-existing chronic kidney disease - requiring dialysis /eGFR \< 30ml/min/1.73m2 * Pre-existing severe respiratory failure - e.g., requiring home oxygen/ home nebulisers/ poor exercise tolerance * Chronic heart failure - NYHA class III and above * Pregnancy * Requirement for immediate immune modulation e.g., plasma exchange, high dose steroids , IV immunoglobulins (does not include vasoplegic dose of steroids or immune modulation for COVID 19) * Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury acute respiratory distress syndrome infectious disease with sepsis Inflammation inflammatory disease injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury ARDS Extracorporeal circulation; complications Inflammation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals of Leicester NHS Trust

    RECRUITING

    Leicester, Leicestershire, LE3 9QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.